Literature DB >> 31603630

Antiobesity Medication Use in 2.2 Million Adults Across Eight Large Health Care Organizations: 2009-2015.

David R Saxon1,2, Sean J Iwamoto1,2, Christie J Mettenbrink3, Emily McCormick3, David Arterburn4, Matthew F Daley5, Caryn E Oshiro6, Corinna Koebnick7, Michael Horberg8, Deborah R Young8, Daniel H Bessesen1,3.   

Abstract

OBJECTIVE: The aim of this study was to examine the prescribing patterns and use of antiobesity medications in a large cohort of patients using data from electronic health records.
METHODS: Pharmacy- and patient-level electronic health record data were obtained on 2,248,407 adults eligible for weight-loss medications from eight geographically dispersed health care organizations.
RESULTS: A total of 29,964 patients (1.3% of total cohort) filled at least one weight-loss medication prescription. This cohort was 82.3% female, with median age 44.9 years and median BMI 37.2 kg/m2 . Phentermine accounted for 76.6% of all prescriptions, with 51.7% of prescriptions being filled for ≥ 120 days and 33.8% filled for ≥ 360 days. There was an increase of 32.9% in medication days for all medications in 2015 compared with 2009. Higher prescription rates were observed in women, black patients, and patients in higher BMI classes. Of 3,919 providers who wrote at least one filled prescription, 23.8% (n = 863) were "frequent prescribers" who wrote 89.6% of all filled prescriptions.
CONCLUSIONS: Weight-loss medications are rarely prescribed to eligible patients. Phentermine accounted for > 75% of all medication days, with a majority of patients filling it for more than 4 months. Less than one-quarter of prescribing providers accounted for approximately 90% of all prescriptions.
© 2019 The Obesity Society.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31603630      PMCID: PMC6868321          DOI: 10.1002/oby.22581

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  25 in total

1.  Time series analyses of the effect of FDA communications on use of prescription weight loss medications.

Authors:  Jason P Block; Niteesh K Choudhry; Daniel P Carpenter; Michael A Fischer; Troyen A Brennan; Angela Y Tong; Olga S Matlin; William H Shrank
Journal:  Obesity (Silver Spring)       Date:  2013-12-02       Impact factor: 5.002

2.  Use of prescription antiobesity drugs in the United States.

Authors:  Christian Hampp; Elizabeth M Kang; Vicky Borders-Hemphill
Journal:  Pharmacotherapy       Date:  2013-09-09       Impact factor: 4.705

3.  Obesity coverage gap: Consumers perceive low coverage for obesity treatments even when workplace wellness programs target BMI.

Authors:  Elizabeth Ruth Wilson; Theodore K Kyle; Joseph F Nadglowski; Fatima Cody Stanford
Journal:  Obesity (Silver Spring)       Date:  2017-01-07       Impact factor: 5.002

4.  CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.

Authors:  Alan J Garber; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Zachary T Bloomgarden; Michael A Bush; Samuel Dagogo-Jack; Ralph A DeFronzo; Daniel Einhorn; Vivian A Fonseca; Jeffrey R Garber; W Timothy Garvey; George Grunberger; Yehuda Handelsman; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Paul D Rosenblit; Guillermo E Umpierrez
Journal:  Endocr Pract       Date:  2018-01-17       Impact factor: 3.443

5.  Treatment of obesity: Pharmacotherapy trends in the United States from 1999 to 2010.

Authors:  Ying Xia; Christina M L Kelton; Jeff J Guo; Boyang Bian; Pamela C Heaton
Journal:  Obesity (Silver Spring)       Date:  2015-08       Impact factor: 5.002

6.  Antiobesity medication use across the veterans health administration: patient-level predictors of receipt.

Authors:  A C Del Re; Susan M Frayne; Alex H S Harris
Journal:  Obesity (Silver Spring)       Date:  2014-06-13       Impact factor: 5.002

7.  Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s.

Authors:  Catherine E Thomas; Elizabeth A Mauer; Alpana P Shukla; Samrat Rathi; Louis J Aronne
Journal:  Obesity (Silver Spring)       Date:  2016-09       Impact factor: 5.002

8.  Treatment satisfaction with different weight loss methods among respondents with obesity.

Authors:  S Gupta; Z Wang
Journal:  Clin Obes       Date:  2016-04

9.  Developing a data infrastructure for a learning health system: the PORTAL network.

Authors:  Elizabeth A McGlynn; Tracy A Lieu; Mary L Durham; Alan Bauck; Reesa Laws; Alan S Go; Jersey Chen; Heather Spencer Feigelson; Douglas A Corley; Deborah Rohm Young; Andrew F Nelson; Arthur J Davidson; Leo S Morales; Michael G Kahn
Journal:  J Am Med Inform Assoc       Date:  2014-05-12       Impact factor: 4.497

10.  Effects of Education and Experience on Primary Care Providers' Perspectives of Obesity Treatments during a Pragmatic Trial.

Authors:  Sean Iwamoto; David Saxon; Adam Tsai; Erin Leister; Rebecca Speer; Hilde Heyn; Elizabeth Kealey; Elizabeth Juarez-Colunga; Kimberly Gudzune; Sara Bleich; Jeanne Clark; Daniel Bessesen
Journal:  Obesity (Silver Spring)       Date:  2018-09-26       Impact factor: 5.002

View more
  19 in total

Review 1.  Treatment of Obesity in Mitigating Metabolic Risk.

Authors:  Sean P Heffron; Johnathon S Parham; Jay Pendse; José O Alemán
Journal:  Circ Res       Date:  2020-05-21       Impact factor: 17.367

2.  Daily transient coating of the intestine leads to weight loss and improved glucose tolerance.

Authors:  Tammy Lo; Yuhan Lee; Chung-Yi Tseng; Yangshuo Hu; Margery A Connelly; Christos S Mantzoros; Jeffrey M Karp; Ali Tavakkoli
Journal:  Metabolism       Date:  2021-10-21       Impact factor: 8.694

Review 3.  Clinical outcomes associated with anti-obesity medications in real-world practice: A systematic literature review.

Authors:  Nadia N Ahmad; Susan Robinson; Tessa Kennedy-Martin; Jiat Ling Poon; Hong Kan
Journal:  Obes Rev       Date:  2021-08-22       Impact factor: 10.867

4.  NAMS 2021 Utian Translational Science SymposiumSeptember 2021, Washington, DCCharting the path to health in midlife and beyond: the biology and practice of wellness.

Authors:  Nanette F Santoro; Helen L Coons; Samar R El Khoudary; C Neill Epperson; Julianne Holt-Lunstad; Hadine Joffe; Sarah H Lindsey; Kara L Marlatt; Patti Montella; Gloria Richard-Davis; Bonny Rockette-Wagner; Marcel E Salive; Cynthia Stuenkel; Rebecca C Thurston; Nancy Woods; Holly Wyatt
Journal:  Menopause       Date:  2022-05-01       Impact factor: 3.310

5.  Reduction in Long-term Mortality after Sleeve Gastrectomy and Gastric Bypass Compared to Non-surgical Patients with Severe Obesity.

Authors:  Anita P Courcoulas; Eric Johnson; David E Arterburn; Sebastien Haneuse; Lisa J Herrinton; David P Fisher; Robert A Li; Mary Kay Theis; Liyan Liu; Brianna Taylor; Julie Cooper; Philip L Chin; Gary G Grinberg; Anirban Gupta; Shireesh Saurabh; Scott S Um; Panduranga R Yenumula; Jorge L Zelada; Karen J Coleman
Journal:  Ann Surg       Date:  2021-08-13       Impact factor: 12.969

Review 6.  Long-Term Weight Loss Strategies for Obesity.

Authors:  Karim Kheniser; David R Saxon; Sangeeta R Kashyap
Journal:  J Clin Endocrinol Metab       Date:  2021-06-16       Impact factor: 5.958

7.  Obesity Pharmacotherapy is Effective in the Veterans Affairs Patient Population: A Local and Virtual Cohort Study.

Authors:  Jay Pendse; Franco Vallejo-García; Andrew Parziale; Mae Callanan; Craig Tenner; José O Alemán
Journal:  Obesity (Silver Spring)       Date:  2021-02       Impact factor: 5.002

8.  Treatment of Obesity: Pharmacotherapy Trends of Office-Based Visits in the United States From 2011 to 2016.

Authors:  Mechelle D Claridy; Kathryn S Czepiel; Simar S Bajaj; Fatima Cody Stanford
Journal:  Mayo Clin Proc       Date:  2021-10-30       Impact factor: 7.616

Review 9.  Strategies to Treat Obesity in Patients With CKD.

Authors:  Kiran Chintam; Alex R Chang
Journal:  Am J Kidney Dis       Date:  2020-10-16       Impact factor: 8.860

Review 10.  Ten things to know about ten cardiovascular disease risk factors.

Authors:  Harold E Bays; Pam R Taub; Elizabeth Epstein; Erin D Michos; Richard A Ferraro; Alison L Bailey; Heval M Kelli; Keith C Ferdinand; Melvin R Echols; Howard Weintraub; John Bostrom; Heather M Johnson; Kara K Hoppe; Michael D Shapiro; Charles A German; Salim S Virani; Aliza Hussain; Christie M Ballantyne; Ali M Agha; Peter P Toth
Journal:  Am J Prev Cardiol       Date:  2021-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.